Coronado Biosciences (NASDAQ:FBIO) has effected a top-level leadership change. The company announced it has appointed Lindsay Rosenwald as its new chairman, president, and CEO, effective yesterday. He replaces outgoing Chairman and CEO Harlan Weisman. 

Rosenwald is not a stranger to the company, having served on its board of directors since 2009. Previous to being tapped to lead the firm, he was a partner and co-portfolio manager of health care-focused asset management firm Opus Point Partners. Prior to that, he was chairman of investment company Paramount BioCapital from 1991 to 2008.

Rosenwald was not the only new hire announced by the company. Coronado has also drafted his Opus co-founder and fellow portfolio manager Michael Weiss to serve on the board as vice-chairman.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.